Growth and business quality are strong, valuation is the relative weak spot (avg 50/100).
Broad-market heuristics · Not a buy/sell signal
Valuation and growth
Valuation
Growth
Above 30x, priced for sustained outperformance
25–30x, paying up for cash generation
Above 10% CAGR, strong compounder
Above 10% CAGR, strong compounder
Business Quality & Capital Allocation
Shrinking >2%, active buybacks
Expanded 1–3pp, steady progress
Net cash position, no leverage concern
Above 20%, exceptional capital efficiency
Medpace Holdings (MEDP) quality: score, margins and returns
Medpace Holdings (MEDP) scores 87/100 on Intrinsiqq's quality score (a high-quality business), a weighted blend of 8 metrics each scored 0 to 100, on 21.4% operating margins and 74.5% ROIC. Every metric is computed from SEC filings; this is analysis, not investment advice.
Frequently asked
Is Medpace Holdings (MEDP) a high-quality business?+
Medpace Holdings scores 87 out of 100 on Intrinsiqq's quality score, a weighted blend of 8 metrics each scored 0 to 100, which rates it a high-quality business on these measures. Recent figures include a 21.4% operating margin and a 74.5% return on invested capital. Quality and price are separate questions: even a great business can be a poor investment if you overpay, so read this score alongside the valuation. The metric-by-metric breakdown is on this scorecard.
What does Medpace Holdings's quality score measure?+
Intrinsiqq's quality score weighs revenue and free-cash-flow growth, operating margins, return on invested capital, change in share count, and balance-sheet strength, each computed from MEDP's SEC filings rather than opinion or sentiment. A higher score means a more durable, capital-efficient business; it is not a buy or sell signal. Open each metric on this page to see exactly where Medpace Holdings scores well and where it falls behind.
What is Medpace Holdings's return on invested capital (ROIC)?+
Medpace Holdings earns about 74.5% on its invested capital, which is exceptional. ROIC measures how much profit a company generates per dollar put to work; sustained ROIC above its cost of capital is one of the clearest signs of a real competitive moat. Compare it to MEDP's margins and growth on this scorecard to judge durability.
How profitable is Medpace Holdings?+
Medpace Holdings runs an operating margin of about 21.4% and a net margin of about 18.2%. Revenue has grown at roughly 22.3% a year recently. High, stable margins usually point to pricing power and operating discipline. Margins are most telling next to growth and returns on capital, all of which feed this quality score. This is analysis from SEC filings, not investment advice.
SourceQuality score computed from the 10-Q filed 16 Oct 2026, covering the period ending 30 Sept 2026, as reported to the SEC. Data last refreshed 23 Oct 2026. How this is calculated.
Fiscal year ends Dec. Sector medians are approximate S&P 500 benchmarks and update periodically. Checks use broad-market heuristics, so sector norms may differ, and the valuation checks are more cyclical than the quality checks.
Peers
Services-Commercial Physical & Biological Research · Pick stocks to compare with MEDP
Held by ETFs
MEDP is in 173 US ETFs. The largest of them, with MEDP's weight in each:
Spot a number that looks wrong? Check it in MEDP's SEC filings or
Download this analysis as a PDF (Pro)
Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Keep analysing MEDP
Create a free account and get 14 days of Premium: every stock and every tool.
- Unlimited stocks
- Stock screener
- Portfolio tracker
- Editable DCF
- Compare side by side
- Unlimited alerts
No card. Moves to Free after, unless you upgrade.
Already have an account?
Or come back tomorrow. Stocks on your watchlist are always free to view.